logo-loader
viewBioLargo, Inc.

BioLargo thrives on a culture of disruption, throwing up game-changing technologies

The California firm’s pipeline includes water treatment technologies, environmental odor control products and medical technologies

A medical researcher
The company is now enjoying its first big commercial success, with its industrial odor product, Odor-No-More

Every year, fledgling startups and established companies alike battle to be recognized as disruptors to their respective industries. It says a lot when a science, technology and environmental company like BioLargo, Inc. (OTCQB:BLGO) invests in scientists and engineers who are disruptors.  

The Westminster, California, company incubates disruptive technologies and has three platforms that it has built over the last 10 years. It has invested nearly US$22mln into clean air, clean water and advanced health care.

“We’ve got 23 Ph.Ds and professional engineers so it’s a truly exceptional group. Direction for us is being purposeful and disruptive,” CEO Dennis Calvert told Proactive Investors' Steve Darling in an interview on the sidelines of the LD Micro conference in Los Angeles.

“We focus on technologies that are disruptors not incremental but things that are going to change the game,” added Calvert.

He explained that the direction of the company is both "purposeful" and "disruptive," and that it narrows the focus to things that are high impact, achievable and have a purpose. 

The company is now enjoying its first big commercial success, with its industrial odor product, Odor-No-More. The product eliminates odor-causing compounds and VOCs and is attracting companies in the solid waste handling and wastewater industries.

“We are enjoying systematic adoption by the largest players in the industry. Literally, our existing salesforce can’t keep up with the volume,” said Calvert.

Wound care

Clyra Medical Technologies holds the exclusive license to commercialize BioLargo’s technology in the Advanced Wound Care industry. The company is waiting on FDA approval for the commercial launch of its advanced wound care products.

“We also have advanced wound care. That’s in the incubator and that product is about to come through the FDA. We have invested about 2.5mln over the last year and half, so we are keen to get it to market,” said Calvert.

Water technology

BioLargo’s Advanced Oxidation System (AOS) combines highly energized iodine molecules with cutting-edge filtration materials to destroy bacteria, reduce BOD, and dismantle soluble organic contaminants. 

“We also have advanced water technology that’s received 59 grants from federal agencies,” said Calvert. “We are just down the commercial pilot phase. We’ve figured out how to scale it up. It works.”

 

Quick facts: BioLargo, Inc.

Price: 0.17 USD

OTCMKTS:BLGO
Market: OTCQB
Market Cap: $27.87 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioLargo, Inc. named herein, including the promotion by the Company of BioLargo, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: BioLargo firing on all cylinders within its engineering,...

BioLargo Inc (OTCMKTS:BLGO) CEO Dennis Calvert tells Proactive the company this week formed a strategic alliance with BKT Company Limited, to explore opportunities for the company's CupriDyne Cleane Industrial Odor technology to be used to treat a South Korean city's water and wastewater...

on 27/9/19

2 min read